Cite
HARVARD Citation
D'Haens, G. et al. (n.d.). S714 52-Week Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn's Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction. American journal of gastroenterology. pp. e497-e498. [Online].